key: cord-0336335-62c81sb3
authors: Kipnis, P.A.; Sullivan, B.J.; Carter, B.M.; Kadam, S.D.
title: TrkB agonists prevent post-ischemic BDNF-TrkB mediated emergence of refractory neonatal seizures in CD-1 pups
date: 2019-12-23
journal: bioRxiv
DOI: 10.1101/2019.12.23.887190
sha: 34b44dea9ec9358f12d299ff4c47569e94a4389e
doc_id: 336335
cord_uid: 62c81sb3

Refractory neonatal seizures do not respond to first-line anti-seizure medications (ASMs) like phenobarbital (PB), a positive allosteric modulator for GABAA receptors, the most widely used ASM to treat neonatal seizures. GABAA receptor-mediated inhibition is dependent upon neuronal chloride regulation. The electroneutral cation-chloride transporter KCC2 mediates neuronal chloride extrusion; an age-dependent increase of KCC2 expression enables the shift of GABAergic signaling from depolarizing to hyperpolarizing. BDNF-TrkB activation following excitotoxic injury recruits downstream targets like PLCγ1, leading to KCC2 hypofunction. This study investigated the efficacy of partial and full TrkB agonists; LM22A-4 (LM), HIOC and Deoxygedunin (DG) respectively, on PB-refractory seizures, post-ischemic TrkB-pathway activation, and KCC2 membrane stability in a P7 CD-1 mouse model of refractory neonatal seizures. Anti-seizure efficacy was determined by quantifying seizure burdens with continuous video-EEG. LM rescued PB-refractory seizures in a sexually dimorphic manner. LM anti-seizure efficacy was associated with a significant reduction in the post-ischemic phosphorylation of TrkB at Y816, a site known to mediate post-ischemic KCC2 hypofunction via PLCγ1 activation. LM additionally rescued ischemia-induced pKCC2-S940 dephosphorylation preserving its membrane stability. HIOC and DG, two novel full TrkB agonists, also rescued PB-refractoriness and post-ischemic TrkB-PLCγ1 pathway activation. Additionally, chemogenetic inactivation of TrkB significantly reduced post-ischemic neonatal seizure burdens at P7. Developmental expression profiles of TrkB and KCC2 in naïve pups identified developmental differences that may underlie the sex-dependent variance in anti-seizure efficacy. These results support a novel role for the TrkB receptor in the emergence of age-dependent refractory neonatal seizures.

Excitotoxic injury has been shown to phosphorylate tyrosine receptor kinase B (TrkB) 59 pathway signaling (1-3). TrkB is activated by its endogenous ligand, the neurotrophin brain- postnatal day 3 (P3) and were allowed to acclimate. Food and water were provided ad libitum. 99 Doses for LM used in vivo and in vitro were determined from previously described in vitro 100 pharmacokinetics (14). Pups of both sexes at P7 and P10 (see Table S1 for sample sizes) were 101 intraperitoneally (IP; Fig. 1A TrkB showed no significant differences between treatment groups (Fig. S3A ). Post-ischemic 343 TrkB activation was analyzed by sex, and no significant sex-dependent differences were found. 344 Total PLCγ1 expression was not significantly modulated by ischemic insult or Post and 345 Pre LM intervention ( Fig. 4D and E) . In contrast, pPLCγ1-Y783 expression was significantly 346 higher both ipsi-and contralateral to ischemic insult, which was rescued both in Post LM and Pre 347 LM groups (Fig. 4D and F ). PLCγ1 and pPLCγ1-Y783 expression levels were also significantly 348 lower ipsilateral to insult (Fig. 4D-F) . The ratio of pPLCγ1-Y783 to total PLCγ1 was not 349 significantly different between treatment groups (Fig. S3B) . 350 TrkB pathway activation is also known to activate downstream ERK1/2 signaling (37).

At P7, Pre LM was the most efficacious treatment paradigm in reducing EEG seizure burdens 352 when quantified as percent seizure suppression (Fig 1E) LM group both ipsi-and contralateral to insult (Fig. S3C) . Post-ischemic TrkB-PLCγ1 pathway activation was not evident in ischemic P10 pups 376 In contrast to P7 pups, no increase in pTrkB-Y816 expression was detected in any 377 treatment group at P10 (Fig. S4A-C) . The Pre LM group showed significantly higher ratios of 378 pTrkB-Y816 to TrkB ipsi-and contralateral to insult (Fig. S4D ). PLCγ1 expression was not 379 different between treated and untreated pups, though Post and Pre LM pups showed ipsilateral 380 downregulation of pPLCγ1-Y783 (Fig. S4E-G) . Ratios of pPLCγ1-Y784 to total PLCγ1 were not 381 affected by LM intervention (Fig. S4H) . No significant KCC2 degradation was detected in the 382 Ligate+PB group (Fig. S4I and J) following ischemia, though Post LM pups showed lower 383 ipsilateral pKCC2-S940 expression (Fig. S4K, L) . In summary, LM intervention showed mild 384 activation of the TrkB pathway, but KCC2 levels were not significantly modulated at P10 when 385 ischemic seizures were responsive to PB. Post and Pre HIOC groups significantly rescued TrkB-pathway activation (Fig. 5D ) and pTrkB-399 Y816 activation bilaterally (Fig. 5E ). Total ERK1/2 expression was not significantly impacted by 400 ischemic insult or any HIOC treatment (Fig. 5F ) similar to LM intervention (Fig. 4H) . In contrast 401 to Pre LM intervention (Fig. 4I) , Post HIOC and Pre HIOC groups did not demonstrate an 402 increase in pERK1/2-T202/Y204 expression (Fig. 5G ). In summary, the differences in LM vs. (Fig. 6A1, A2 and B) . Developmentally, TrkB expression in the cortex of female pups 426 declined significantly from P5 to P21. In contrast, TrkB expression in males did not decline 427 significantly from P5 to P21. Both female and male pups showed significant decline of pTrkB-428 Y816 expression from P5 to P21 (Fig. 6C ). In the cortex, ratios of pTrkB-Y816 to total TrkB 429 were not significantly different by sex or age (Fig. 6D) . 430 Similar to the results found in the cortex, TrkB expression in the hippocampi of female 431 pups declined significantly from P5 to P21, whereas TrkB expression in males did not decline 432 significantly (Fig. 6E1, E2 , and F). pTrkB-Y816 expression also declined significantly in the 433 hippocampi of female pups from P5 to P21 (Fig. 6G) . Ratios of pTrkB-Y816 to total TrkB were 434 not sexually dimorphic and did not change significantly between ages of P5 to P21 in the 435 hippocampus (Fig. 6H ). In deep gray matter, TrkB expression decreased significantly between 436 P5 and P21 in females, whereas TrkB expression remained stable and did not decline 437 significantly in males (Fig. 6I1, I2 , and J). pTrkB-Y816 expression decreased significantly in 438 both females and males from P5 to P21 (Fig. 6I1, I2 , and K). However, ratios of pTrkB-Y816 to 439 total TrkB were not different between sexes sexually dimorphic and did not change significantly 440 between ages of P5 to P21 in the deep gray matter (Fig. 6L) . These results suggest that sexually 441 dimorphic expression levels of TrkB in the cortex may underlie the sexually dimorphic seizure 442 susceptibility and rescue of PB-refractoriness with LM ( Fig. 1 and 2) , as neonatal seizures are 443 cortical. Furthermore, the attenuation of pTrkB-Y816 from P5 to P21 in both males and females 444 suggests that TrkB pathway activation decreases with age. 445 At P5, females showed significantly higher PLCγ1 and pPLCγ1-Y783 expression in the 446 cortex than at P21 (Fig. S5A and B) . In contrast, PLCγ1 and pPLCγ1-Y783 expression in males 447 was not significantly different between age groups. The hippocampus and deep gray matter did 448 not show significant differences between sexes in PLCγ1 or pPLCγ1-Y783 expression during 449 development (Fig. S5D, E, G, and H) . Similarly, ratios of pPLCγ1-Y783 to total PLCγ1 were not 450 significantly different between sexes during development for all examined brain regions (Fig. 451 S5C, F, and I). Males showed a significant increase in KCC2 expression between P5 and P21, and P7 455 and P21, whereas females did not (Fig. S5J and K) . pKCC2-S940 was not found to be 456 significantly dephosphorylated in both sexes ( Fig. S5J and K) . In contrast, only females showed 457 significantly lower ratios of pKCC2-S940 to total KCC2 in the cortex (Fig. S5L ). In the 458 hippocampus, both males and females did not show a significant change in KCC2 expression 459 ( Fig. S5M and N) . pKCC2-S940 expression and ratios of pKCC2-S940 to total KCC2 were not 460 found to be sexually dimorphic between ages (Fig. S5M-O) . In deep gray matter, both females 461 and males showed significantly lower expression of pKCC2-S940 at P21 (Fig. S5P-R) TrkB signaling is known to be sexually dimorphic in a region-specific manner (80-82). 584 In BDNF +/mice, greater levels of pTrkB-Y705 activation were shown in the frontal cortex and 585 striatum of male mice 10-16 weeks of age compared to females. These changes in TrkB 586 phosphorylation state were accompanied by concomitant increases in ERK1/2 587 phosphorylation(80), suggesting a differential signaling mechanism that was sexually dimorphic. 588 The developmental expression of KCC2 is also known to increase with age, and this 589 developmental profile is sex-dependent, with female pups expressing higher levels than male 590 pups (15, 83, 84) Table S1 normalized to housekeeping protein β-actin. Phospho-proteins were also normalized to their 948 respective total protein (see Figure S3 ). * indicate differences between treatment group and naïve 949 controls; # indicated differences between contralateral and ipsilateral hemispheres within groups. 

Activity-Dependent Activation of TrkB 612 Neurotrophin Receptors in the Adult CNS

Acute TrkB inhibition rescues phenobarbital-resistant seizures in a 614 mouse model of neonatal ischemia

Immunohistochemical Evidence of Seizure-Induced 616 Activation of trkB Receptors in the Mossy Fiber Pathway of Adult Mouse Hippocampus

BDNF: A Key Factor with

Multipotent Impact on Brain Signaling and Synaptic Plasticity

Dose-dependent reversal of KCC2 hypofunction and 621 phenobarbital-resistant neonatal seizures by ANA12

Direct Protein Kinase C-623 dependent Phosphorylation Regulates the

NMDA receptor activity downregulates KCC2 626 resulting in depolarizing GABA(A) receptor mediated currents

The GABA Excitatory/Inhibitory Shift in Brain 628 Maturation and Neurological Disorders. The Neuroscientist

Developmental 630 Expression Patterns of KCC2 and Functionally Associated Molecules in the Human Brain

Expression of GABA Signaling Molecules 634 KCC2, NKCC1, and GAD1 in Cortical Development and Schizophrenia

BDNF-induced TrkB activation down-regulates the K+-Cl− cotransporter 638 KCC2 and impairs neuronal Cl− extrusion

Mechanism of Activity-Dependent Downregulation of the Neuron-Specific K-Cl Cotransporter KCC2

How theories evolved concerning the mechanism of action of barbiturates

Small 645 molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents

Age-and sex-dependent susceptibility 648 to phenobarbital-resistant neonatal seizures: role of chloride co-transporters. Frontiers in Cellular 649 Neuroscience

N-acetyl serotonin derivatives as potent 651 neuroprotectants for retinas

Deoxygedunin, a Natural Product with Potent Neurotrophic Activity in Mice

Gram-scale, chemoselective synthesis of N-656 [2-(5-hydroxy-1H-indol-3-yl)ethyl]-2-oxopiperidine-3-carboxamide (HIOC)

Expression of BDNF and trkB as a function of age and 659 cognitive performance

Effect of aging on the expression of BDNF 661 and TrkB isoforms in rat pituitary

Age-related changes in brain-derived neurotrophic 663 factor and tyrosine kinase receptor isoforms in the hippocampus and hypothalamus in male rats

BDNF and trkB mRNA expression in 666 the hippocampus and temporal cortex during the human lifespan

Pharmaco-resistant Neonatal Seizures: Critical Mechanistic Insights 668 from a Chemoconvulsant Model

A chemical-genetic approach to studying neurotrophin signaling

Sex-Dependent Signaling Pathways Underlying Seizure 673 Susceptibility and the Role of Chloride Cotransporters

Dissociated Gender-Specific Effects of Recurrent Seizures on GABA Signaling in CA1 675 Pyramidal Neurons: Role of GABAA Receptors

U-shaped dose-responses in biology, toxicology, and public health

NKCC1 transporter facilitates seizures in the developing brain

Acute inhibition of neurosteroid estrogen synthesis suppresses status epilepticus in 682 an animal model

Ischemic injury suppresses hypoxia-induced 684 electrographic seizures and the background EEG in a rat model of perinatal hypoxic-ischemic encephalopathy

Characterisation of neonatal seizures and their treatment using continuous EEG 689 monitoring: a multicentre experience

Strain-related brain injury in neonatal mice subjected to hypoxia-692 ischemia

Strain-Related Differences in Mouse Neonatal Hypoxia-Ischemia

C57BL/6J and C57BL/6N substrains differentially influence 696 phenotype severity in the Scn1a+/− mouse model of Dravet syndrome

CRHR1 exacerbates the glial inflammatory 698 response and alters BDNF/TrkB/pCREB signaling in a rat model of global cerebral ischemia: implications for 699 neuroprotection and cognitive recovery

Disruption of TrkB-Mediated Phospholipase 702 C Signaling Inhibits Limbic Epileptogenesis

Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated 705 by ERK and PI3-kinase pathways

Small-molecule modulation of neurotrophin receptors: a strategy for the treatment 707 of neurological disease

Plasma 711 Brain-Derived Neurotrophic Factor Levels in Newborn Infants with Neonatal Abstinence Syndrome

Regulated neurotrophin receptor responsiveness during 714 neuronal migrationand early differentiation

The Role of BDNF in Age-Dependent Changes of Excitatory and Inhibitory 716

Synaptic Markers in the Human Prefrontal Cortex

Trk receptors

Neurotrophins and their receptors: a convergence point for many signalling pathways

BDNF signaling in the formation, maturation and plasticity of 721 glutamatergic and GABAergic synapses

Trk receptors: roles in neuronal signal transduction

BDNF and epilepsy: too much of a good thing? 725

Jasper's Basic Mechanisms of the Epilepsies

Transcript specificity in BDNF-regulated protein synthesis. 730 Neuropharmacology. 76 Pt C

Epigenetic Regulation of BDNF Gene during Development and Diseases

Functional Role of BDNF Production 735 from Unique Promoters in Aggression and Serotonin Signaling

Pro-Brain-Derived Neurotrophic Factor (proBDNF)-Mediated p75NTR Activation 739

Promotes Depolarizing Actions of GABA and Increases Susceptibility to Epileptic Seizures

Neuronal 742 chloride accumulation and excitatory GABA underlie aggravation of neonatal epileptiform activities by 743 phenobarbital

TrkB from Phospholipase Cγ1 Prevents Epilepsy Induced by Status Epilepticus

Disruption of TrkB-mediated PLC+¦ 747 signaling inhibits limbic epileptogenesis

Locally Reducing KCC2 Activity in the Hippocampus is Sufficient to Induce Temporal Lobe Epilepsy

Identification of KCC2 Mutations in Human Epilepsy Suggests 752 Strategies for Therapeutic Transporter Modulation

Peptides derived from the solvent-755 exposed loops 3 and 4 of BDNF bind TrkB and p75NTR receptors and stimulate neurite outgrowth and 756 survival

Mimetics of brain-derived 758 neurotrophic factor loops 1 and 4 are active in a model of ischemic stroke in rats

Hippocampal long-term potentiation is supported by presynaptic and postsynaptic tyrosine receptor kinase B-762 mediated phospholipase Cgamma signaling

TrkB signalling pathways in LTP and learning

BDNF Protects the Neonatal Brain from Hypoxic-Ischemic InjuryIn Vivo via the 765 ERK Pathway

Roskoski, ERK1/2 MAP kinases: structure, function, and regulation

Molecule TrkB Neurotrophin Receptor Partial Agonist as Possible Treatment for Experimental Nonarteritic 769 Anterior Ischemic Optic Neuropathy

Partial TrkB receptor activation suppresses cortical 771 epileptogenesis through actions on parvalbumin interneurons

Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. 774 Annals of Neurology

Is autism caused by early hyperactivity of brain-derived neurotrophic factor? Medical Hypotheses

Autism spectrum disorders following in utero exposure to antiepileptic drugs

The prevalence of 782 neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs

Fetal valproate syndrome and 785 autism: additional evidence of an association

Increased BDNF expression in fetal brain in the valproic acid 787 model of autism

Oxytocin-mediated GABA 790 inhibition during delivery attenuates autism pathogenesis in rodent offspring

Pyramidal neuron growth and increased hippocampal 793 volume during labor and birth in autism

Delayed Maturation of Fast-Spiking Interneurons Is Rectified by Activation of the TrkB Receptor in the 796 Mouse Model of Fragile X Syndrome

The receptor tyrosine 798 kinase TrkB signals without dimerization at the plasma membrane

Ligand signature in the 800 membrane dynamics of single TrkA receptor molecules

Mechanisms of Activation of Receptor Tyrosine Kinases: Monomers or Dimers

The in vivo contribution of motor neuron TrkB receptors to mutant SOD1 motor neuron disease

ANOVA. (D) EEG ictal events for Ligate+PB, Post LM, and Pre LM treated P10 pups

nd Ligate+PB vs. 1 st Ligate+PB), **** p<0.0001 (2 nd Post LM vs. 1 st Post LM, 912 and 2 nd Pre LM vs. 1 st Pre LM) by two-way ANOVA. (E) EEG mean ictal durations for

LM treated P7 pups. * p<0.05 (2 nd Ligate+PB vs. 1 st Ligate+PB) 914 by two-way ANOVA. (F) EEG mean ictal durations for Ligate+PB, Post LM, and Pre LM 915 treated P10 pups. (G) EEG seizure burdens by sex for Ligate+PB, Post LM, and Pre LM treated 916 P7 pups. * p<0.05 (2 nd Female Post LM vs. 1 st Female Post LM, and 2 nd Male Pre LM vs

Male Pre LM), ** p<0.01 (2 nd Female Pre LM vs. 1 st Female Pre LM) by two-way ANOVA. (H) 918 EEG seizure burdens by sex for Ligate+PB, Post LM, and Pre LM treated P10 pups. * p<0.05 919 (2 nd Male Ligate+PB vs. 1 st Male Ligate+PB, 2 nd Female Post LM vs. 1 st Female Post LM, and 920 2 nd Male Pre LM vs. 1 st Male Pre LM), **** p<0.0001 (2 nd Female Pre LM vs. 1 st Female Pre 921 LM) by two-way ANOVA. @ p<0.05 by two-tailed t test. (I) EEG ictal events by sex for

LM treated P7 and (J) P10 pups. (K) EEG mean ictal durations by 923 sex for Ligate+PB, Post LM, and Pre LM treated P7 and (L) P10 pups

HIOC, and Pre HIOC treated P7 pups. * p<0.05 by two-way ANOVA. (C) EEG seizure burdens 976 for Ligate+PB, Post HIOC, and Pre HIOC treated P7 pups. * p<0.05 by two-way ANOVA

0001 by one-way ANOVA. # indicated 981 differences between contralateral and ipsilateral hemispheres within groups; # p<0.05 by two-982 tailed t test. (F) Contralateral (L) and ipsilateral (R) ERK1/2 expression 24h after ischemic insult 983 for all treatment groups. (G) Contralateral (L) and ipsilateral (R) pERK1/2-T202/Y204 984 expression 24h after ischemic insult for all treatment groups. (H) Contralateral (L) and ipsilateral 985 (R) KCC2 expression 24h after ischemic insult for all treatment groups. #### p<0.0001 by two-986 tailed t test. (I) Contralateral (L) and ipsilateral (R) pKCC2-S940 expression 24h after ischemic 987 insult for all treatment groups. * p<0.05 by one-way ANOVA. ### p<0.001 by two-tailed t test. 988 (J) EEG percent seizure suppression for Ligate+PB, Post DG, and Pre DG treatment groups 989 plotted against left y-axis. ** p<0.01 by one-way ANOVA. EEG percent seizure suppression by 990 sex for Ligate+PB

TrkB expression in cortical tissue from P5 to P21. ** p<0.01, *** p<0.001, **** 1004 p<0.0001 by two-way ANOVA. (C) pTrkB-Y816 expression in cortical tissue from P5 to P21. # 1005 p<0.05 signified difference between sexes at a given age. * p<0.05, ** p<0.01, **** p<0.0001 1006 by two-way ANOVA. (D) pTrkB-Y816 normalized to total TrkB in cortical tissue from P5 to 1007 P21. (E1) Representative Western blots showing TrkB and pTrkB-Y816 expression in 1008 hippocampus for all female and (E2) male age groups. (F) TrkB expression in hippocampal 1009 tissue from P5 to P21

Western blots showing TrkB and pTrkB-Y816 expression in deep gray matter for all female and 1013 (I2) male age groups. (J) TrkB expression in deep gray matter from P5 to P21. * p<0.05 by two-1014 way ANOVA. (K) pTrkB-Y816 expression in deep gray matter from P5 to P21

Ligate+PB) by one-way ANOVA. (B) EEG percent seizure suppression by sex for Ligate+PB

Post LM 2.5, and Pre LM 2.5 treated P7 pups. (C) Representative Western blot showing 1044 membrane and cytosolic TrkB and pTrkB-Y816 expression after incubation with TrkB agonists

Representative Western blot showing membrane and cytosolic KCC2 and pKCC2-S940 1046 expression after incubation with TrkB agonists. (E) Ratio of pTrkB-Y816 to total TrkB at the 1047 plasma membrane. (F) Ratio of pKCC2-S940

Representative raw 10 min EEG trace from 0.5-50Hz of refractory ischemic 1053 seizures from a neonatal P7 mouse pup. (B) A single ictal event from A (solid bar -2 min 1054 expanded timescale raw trace). (C and D) Filtered EEG trace of the same ictal event in B filtered 1055 to show low frequency and high frequency components of the same ictal event (0.5-13Hz and 1056 13-50Hz). (E) EEG percent power suppression for Ligate+PB, Post LM, and Pre LM treated P7 1057 pups. (F) EEG 1 st and 2 nd hour EEG powers for Ligate+PB, Post LM, and Pre LM treated P7 1058 pups. (G) Percent power suppression plotted as a function of percent seizure suppression

Normalization of phospho-proteins to their total proteins in P7 ischemic pups. (A) 1064 pTrkB-Y816 normalized to total TrkB for Naïve, Ligate+PB, Post LM, and Pre LM at P7. # 1065 signified hemispheric differences within groups, ## p<0.01 by two-tailed t test. (B) pPLCγ1-1066 Y783 normalized to total PLCγ1 for Naïve

Representative Western blots showing PLCγ1 and pPLCγ1-1084 Y783 expression. (F) Contralateral (L) and ipsilateral (R) PLCγ1 expression 24h after ischemic 1085 insult for all treatment groups. (G) Contralateral (L) and ipsilateral (R) pPLCγ1-Y783 expression 1086 24h after ischemic insult for all treatment groups. # signified hemispheric differences within 1087 groups

Contralateral (L) and ipsilateral (R) KCC2 expression 24h after 1090 ischemic insult for all treatment groups. (K) Contralateral (L) and ipsilateral (R) pKCC2-S940 1091 expression 24h after ischemic insult for all treatment groups. # p<0.05 by two-tailed t test. (L) 1092 KCC2 normalized to total pKCC2-S940 for Naïve, Ligate+PB, Post LM, and Pre LM at P10. # 1093 signified hemispheric differences within groups. # p<0.05. total PLCγ1 in cortical tissue from P5 to P21. (D) Representative Western blots 1113 showing PLCγ1 and pPLCγ1-Y783 expression in hippocampal tissue

PLCγ1 and pPLCγ1-Y783 expression in 1117 deep gray matter from P5 to P21. (I) pPLCγ1-Y783 normalized to total PLCγ1 in hippocampal 1118 tissue from P5 to P21. (J) Representative Western blots showing KCC2 and pKCC2-S940 1119 expression in cortical tissue. (K) KCC2 and pKCC2-S940 expression in cortical tissue from P5 1120 to P21. ** p<0.01 by two-way ANOVA. (L) pKCC2-S940 normalized to total KCC2 in cortical 1121 tissue from P5 to P21. * p<0.05, ** p<0.01 by two-way ANOVA. (M) Representative Western 1122 blots showing KCC2 and pKCC2-S940 expression in hippocampal tissue. (N) KCC2 and 1123 pKCC2-S940 expression in cortical tissue from P5 to P21. (O) pKCC2-S940 normalized to total 1124 KCC2 in hippocampal tissue from P5 to P21. (P) Representative Western blots showing KCC2 1125 and pKCC2-S940 expression in deep gray matter. (Q) KCC2 and pKCC2-S940 expression in 1126 deep gray matter from P5 to P21. ** p<0.01, *** p<0.001 by two-way ANOVA. (R) pKCC2-1127 S940 normalized to total KCC2 in deep gray matter from P5 to P21